Exclusive: Dems call for details on Trump drug price deals
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Aïda Amer/Axios
Calls for more details about President Trump's drug pricing deals are intensifying, with Senate Democrats set to unveil legislation Tuesday as part of a push questioning whether the arrangements really help consumers.
Why it matters: The "most favored nation" deals with 16 pharmaceutical companies are a signature health policy accomplishment the administration is already touting ahead of the midterm elections.
- But polling indicates most of the public is skeptical Trump will deliver and lower drug costs for people like them.
Driving the news: The legislation, shared first with Axios, would require Health Secretary Robert F. Kennedy Jr. to make terms of the confidential deals public.
- It is led by Senate Finance Committee ranking Democrat Ron Wyden of Oregon, joined by several potential 2028 presidential contenders like Arizona Sens. Mark Kelly and Ruben Gallego, as well as Bernie Sanders (I-Vt.), Elizabeth Warren (D-Mass.) and all of the Finance panel Democrats.
- While it stands little chance of advancing, the measure raises doubts about the administration's transparency — and whether the drugmakers may actually benefit.
- "After spending the last year parading Big Pharma CEOs through the Oval Office, all Trump has to show for it are a handful of sweetheart deals that shower goodies on these companies while Americans continue paying high prices for medicines they count on," Wyden said.
An accompanying Democratic report states that "Americans can reasonably conclude, in the absence of further transparency, that these 'deals' are a sham" with "little to no savings to patients."
Between the lines: Lowering drug prices has long been a popular political goal, and the battle lines over credit are forming heading into November's midterms.
- More than two-thirds of Democrats, independents and Republicans said in a KFF poll last month that there's not enough regulation to limit the price of drugs.
The big picture: Trump frequently makes sweeping claims about how much the deals are lowering drug prices.
- Trump said in his State of the Union that he is "ending the wildly inflated cost of prescription drugs like has never happened before."
- "Other presidents tried to do it, but they never could," he added.
Yes, but: The administration is refusing to disclose what it agreed to, saying the deals contain confidential and proprietary information.
- From what little is publicly known, there are major limitations to how sweeping the reductions will be.
- They are focused on Medicaid and newly launched drugs, meaning drug prices for people on Medicare or private insurance — a majority of the country — are mostly not included.
- In their report, Democrats also argue that drug prices in Medicaid are already very low, leaving little room for improvement.
Trump has also touted the government's TrumpRx website as a way for people who make cash purchases to save money.
- But Democrats counter most Americans get drugs through their insurance and won't benefit from the site. Many of the drugs are also available for less money outside the site in generic form anyway.
What we're watching: Trump is pressuring Congress to write the most-favored nation deals into law.
- GOP congressional leadership has long been cool to the idea, which runs against traditional Republican orthodoxy on free markets.
- But the threat of tariffs on drug imports could persuade more companies to cut deals with the administration in the coming weeks in exchange for tariff relief for the remainder of Trump's term.
